The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 53 | — | 20.1x | Near average | |
Growth | 60 | 1.0% | 5.6% | Near average | |
Quality | 24 | -97.1% | 7.6% | Below average | |
Safety | 25 | 0.2x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Bionano Genomics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Bionano Genomics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Bionano Genomics stock exhibits a state of extreme uncertainty and a sharp decline in analyst coverage, as current forecasts are limited to only one analyst with an average target of 46.5 dollars, a figure reflecting a massive and unrealistic gap compared to the current market price (1.24 dollars). The stark contrast between the highest target price (175 dollars) and the lowest (1 dollar) indicates a total dispersion in estimates and an absence of institutional consensus, making the average forecasts statistically misleading.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.